Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole

Abstract

Phyllis M Salzman,1 Arash Raoufinia,2 Susan Legacy,3 Pedro Such,4 Anna Eramo5 1Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, 2Clinical Pharmacology, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, 3US Medical Affairs, Neuroscience, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA; 4Medical Affairs Psychiatry, H. Lundbeck A/S, Valby, Denmark; 5Global Clinical Development, CNS, Lundbeck LLC, Deerfield, IL, USA Abstract: Maintaining therapeutic plasma concentrations of an antipsychotic agent is essential in preventing relapse of symptoms in schizophrenia. Long-acting injectable (LAI) formulations provide extended exposure to antipsychotic therapy and have been useful in addressing treatment nonadherence. Aripiprazole is an atypical antipsychotic used in the treatment of schizophrenia and is available in 2 chemically different (aripiprazole monohydrate and aripiprazole lauroxil [AL]) and pharmaceutically different LAI formulations (aripiprazole once-monthly 400 mg [AOM 400] and AL). The pharmaceutical difference is that AL, unlike AOM 400, is a prodrug that requires additional metabolic steps to form the active drug aripiprazole. We present data demonstrating that aripiprazole plasma concentrations are similar for AOM 400 and the 882 mg dose of AL when administered once every 4 weeks and that both provide similar therapeutic plasma concentrations of aripiprazole when compared with therapeutic oral doses. Keywords: long-acting injectable, aripiprazole, plasma concentrations, dosing, schizophrenia

Keywords

• long-acting injectable
• aripiprazole
• plasma concentrations
• dosing
• schizophrenia